Warfarin dose requirement and CYP2C9 polymorphisms -: Reply

被引：10

作者：

Aithal, GP

Day, CP

Kesteven, PJL

Daly, AK ^{[1
]}

机构：

[1] Univ Newcastle Upon Tyne, Sch Med, Dept Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England

[2] Univ Newcastle Upon Tyne, Sch Med, Dept Pharmacol Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England

来源：

LANCET | 1999年 / 353卷 / 9168期

关键词：

D O I：

10.1016/S0140-6736(05)77185-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：1972 / 1973

页数：2

相关论文

共 4 条

[1] COLVIN BT, 1990, J CLIN PATHOL, V43, P177
[2] Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms
Haining, RL
Hunter, AP
Veronese, ME
Trager, WF
Rettie, AE
[J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1996, 333 (02) : 447 - 458
[3] Genetic control of anticoagulation
Mannucci, PM
[J]. LANCET, 1999, 353 (9154) : 688 - 689
[4] IMPAIRED (S)-WARFARIN METABOLISM CATALYZED BY THE R144C ALLELIC VARIANT OF CYP2C9
RETTIE, AE
WIENKERS, LC
GONZALEZ, FJ
TRAGER, WF
KORZEKWA, KR
[J]. PHARMACOGENETICS, 1994, 4 (01): : 39 - 42